Search results for "Liver Function Test"

showing 10 items of 80 documents

Placenta-derived CD95 ligand causes liver damage in hemolysis, elevated liver enzymes, and low platelet count syndrome.

2004

Background & Aims: The HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome is a life-threatening complication during pregnancy. The associated liver disease may be severe, and maternal hepatic complications may progress to the point that transplantation becomes necessary. CD95 (APO-1, Fas)-mediated apoptosis of liver cells is one of the major pathogenic mechanisms during liver disease. The interaction of CD95 with its ligand, CD95L(FasL), induces apoptosis and thus the source of the death-inducing ligand is critical for understanding the pathomechanism of liver damage involving the CD95-system. Methods: Sera from HELLP patients were analyzed and used in cell culture experiment…

medicine.medical_specialtyHELLP SyndromeFas Ligand ProteinHELLP syndromePlacentaApoptosisBiologyHepatic ComplicationFas ligandAcute fatty liver of pregnancyLiver diseaseJurkat CellsMicePregnancyInternal medicinemedicineAnimalsHumansCells CulturedTransaminasesMembrane GlycoproteinsHepatologymedicine.diagnostic_testLiver cellGastroenterologymedicine.diseaseHemolysisMolecular WeightEndocrinologyLiverCancer researchHepatocytesFemaleLiver function testsGastroenterology
researchProduct

Evidence-based medicine and the problem of healthy volunteers

2017

Abstract Healthy controls are subjects without the disease being studied but may have other conditions indirectly affecting outcome. In the present epidemics of obesity a few subjects with undiagnosed nonalcoholic fatty liver disease enter clinical studies as controls, producing biased results. Stricter selection criteria should be considered to prevent this risk.

medicine.medical_specialtyLiver EnzymesSpecialties of internal medicinePredictive Value of TestDiseaseGastroenterology03 medical and health sciences0302 clinical medicineClinical trialsLiver Function TestsPredictive Value of TestsReference ValuesNon-alcoholic Fatty Liver DiseaseLiver enzymeInternal medicineNAFLDHealthy volunteersNonalcoholic fatty liver diseasemedicineHumansReference ValueObesitySelection (genetic algorithm)Evidence-Based MedicineHepatologybusiness.industryLiver Function TestPatient SelectionLiver enzymeControl groupGeneral MedicineEvidence-based medicineClinical trials. Control group. Liver Enzymes. NAFLD. Obesitymedicine.diseaseObesityHealthy VolunteerHealthy VolunteersClinical trialClinical trialRC581-951030211 gastroenterology & hepatologybusiness030217 neurology & neurosurgeryHuman
researchProduct

Soluble complement receptor type 1 (sCR1) in chronic liver diseases: serum levels at different stages of liver diseases.

1998

SUMMARYComplement receptor type 1 (CR1) is an integral membrane protein of many haematopoietic cells and plays an important role in the clearance of complement-associated immune complexes, favouring their transport to liver and spleen macrophages. A small amount of soluble CR1 (sCR1) is also found in plasma and might originate directly from release of leucocytes and other circulating cells. In previous studies, an increase in serum sCR1 level has been observed in liver cirrhosis and end-stage renal failure. High levels have also been found in patients with some haematologic malignancies. sCR1 serum levels were measured using a specific double sandwich ELISA assay. The present study demonstr…

Liver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma HepatocellularImmunologyChronic liver diseaseLiver diseaseImmune systemInternal medicinemedicineImmunology and AllergyHumansmedicine.diagnostic_testbusiness.industryLiver Diseasesmedicine.diseaseHepatitis CImmune complexReceptors ComplementEndocrinologyHepatocellular carcinomaImmunologyChronic DiseaseOriginal ArticleLiver functionLiver function testsbusinessClinical and experimental immunology
researchProduct

Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia

2018

Background The World Health Organization has set an ambitious goal of eliminating viral hepatitis as a major public health threat by 2030. However, in sub-Saharan Africa, antiviral treatment of chronic hepatitis B (CHB) is virtually unavailable. Herein, we present the 1-year results of a pilot CHB treatment program in Ethiopia. Methods At a public hospital in Addis Ababa, CHB patients were treated with tenofovir disoproxil fumarate based on simplified eligibility criteria. Baseline assessment included liver function tests, viral markers, and transient elastography (Fibroscan). Changes in laboratory markers were analyzed using Wilcoxon signed-rank tests. Adherence to therapy was measured by …

AdultLiver CirrhosisMalemedicine.medical_specialtyAdolescentEpidemiologylcsh:MedicinePilot ProjectsAntiviral therapymedicine.disease_causeAntiviral AgentsYoung Adult03 medical and health sciencesHepatitis B Chronic0302 clinical medicineChronic hepatitisInternal medicineEpidemiologymedicineHumansPilot program030212 general & internal medicineViral hepatitisTenofovirHepatitis B virusmedicine.diagnostic_testbusiness.industryPublic healthlcsh:RGeneral MedicineMiddle AgedViral Loadmedicine.diseaseResource-limited settingsTreatment Adherence and ComplianceTreatment OutcomeFemale030211 gastroenterology & hepatologyEthiopiaTransient elastographybusinessLiver function testsViral hepatitisBiomarkersFollow-Up StudiesResearch ArticleBMC Medicine
researchProduct

Acute and chronic hepatitis in childhood leukemia: a multicentric study from the Italian Pediatric Cooperative Group for Therapy of Acute Leukemia (A…

1985

The incidence of acute and chronic liver damage and its relation to hepatitis B virus (HBV) infection was evaluated in 164 consecutive children with acute leukemia seen in ten Italian hemato-pediatric units. Thirteen out of 164 children (7.9%) had acute hepatitis (AH) during treatment, while 8/90 (8.8%) showed an acute exacerbation of liver damage within 6 months after therapy withdrawal. Seven of the 13 children with AH while on therapy were HBsAg positive. In 12/13 cases, liver disease progressed to chronicity. Five of eight children who developed AH after completion of treatment were HBsAg positive. Eighty-nine patients (54.2%) developed biochemical evidence of chronic hepatitis during t…

MaleCancer Researchmedicine.medical_specialtyHBsAgChildhood leukemiaExacerbationAdolescentmedicine.disease_causeGastroenterologyacute hepatitisHepatitisLiver diseasechronic hepatitiLiver Function TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChildHepatitis B virusAcute leukemiaHepatitis B Surface AntigensLeukemiabusiness.industryLiver cellacute hepatitichildhood leukemiavirus diseasesInfantmedicine.diseaseacute hepatitis; chronic hepatitis; childhood leukemiaHepatitis BLeukemia LymphoidLeukemiaAcute and chronic hepatitis; childhood leukemia; multicentric study from AIEOPOncologyItalyChild PreschoolPediatrics Perinatology and Child HealthImmunologyAcute DiseaseFemalechronic hepatitisChemical and Drug Induced Liver InjurybusinessMedical and pediatric oncology
researchProduct

Hepatocellular carcinoma: comparison of two different periods at the same center.

2010

Aims: To analyze the main etiological factors and some clinical characteristics of patients with HCC at diagnosis and to compare them with those we described ten years ago. Methods: 179 patients were included in Group 1, while 132 patients were included in Group 2. For all patients age, sex, serum markers of hepatitis B and C viruses, alcohol consumption, serum alpha feto-protein (AFP) levels and the main liver function parameters at HCC diagnosis were recorded. Results: Mean age was 66.0 years for Group 1 and 69.0 for Group 2 (P=0.005). HCV was responsible for 80.3% of HCC cases in Group 2 versus 72% in Group 1 (P=0.005). HBV alone and co-infection of HCV+HBV decreased, but not significant…

OncologyAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaCarcinoma HepatocellularTime FactorsAlcohol DrinkingAlpha (ethology)Gastroenterologyhepatocellular carcinoma Etiology Staging DiagnosisLiver diseaseLiver Function TestsInternal medicineInternal MedicinemedicineHumansAgedNeoplasm StagingAged 80 and overmedicine.diagnostic_testbusiness.industryLiver NeoplasmsHepatitis CHepatitis BMiddle Agedmedicine.diseaseHepatitis BHepatitis Cdigestive system diseasesItalyHepatocellular carcinomaEtiologyFemaleLiver functionalpha-FetoproteinsLiver function testsbusinessEuropean journal of internal medicine
researchProduct

Assessment of treatment response in hepatocellular carcinoma: a review of the literature

2013

Hepatocellular carcinoma (HCC) has a high incidence all over the world. Even if the primary end point of treatment of HCC is survival, radiological response could be a surrogate end point of survival, and could have a key role in clinical management. Since 1950 several radiological response criteria have been applied; however, it was not until 2000 that specific criteria for HCC were introduced by the European Association for the Study of the Liver (EASL), and these were then standardized in 2010 with the development of the modified Response Evaluation Criteria for Solid Tumors (mRECIST) for HCC. The purpose of this brief review is to compare data in literature regarding the application an…

OncologyCancer ResearchTreatment responsemedicine.medical_specialtyCarcinoma HepatocellularLiver Function TestsInternal medicineClinical endpointHumansMedicineResponse criteriaNeoplasm StagingRandomized Controlled Trials as Topicbusiness.industrySurrogate endpointIncidence (epidemiology)Liver NeoplasmsGeneral MedicinePrognosismedicine.diseaseSurvival Analysisdigestive system diseasesRadiographyClinical PracticeTreatment OutcomeOncologyRadiological weaponHepatocellular carcinomabusinessFuture Oncology
researchProduct

Significance of the effective remnant liver volume in major hepatectomies

2005

The aim of this study is to identify the minimum safe amount of effective remnant liver volume (ERLV) in patients undergoing a major hepatectomy. Thirty-eight consecutive major hepatectomies (resection of ≥3 Couinaud segments) performed between July 1999 and March 2004 in which a frozen section liver biopsy was obtained were included. No patient had chronic viral hepatitis, cirrhosis, or cholestasis. The total liver volume (TLV) was calculated using the Vauthey formula, and the postsurgical liver volume (PSLV) was derived by subtracting the estimated volume of liver resected from the TLV. The PSLV minus the percentage of macrovesicular steatosis as nonfunctional liver was defined as the ef…

Malemedicine.medical_specialtyCirrhosisRisk AssessmentCohort StudiesPostoperative ComplicationsCholestasisLiver Function TestsmedicineHepatectomyHumansSurvival analysisProbabilityRetrospective StudiesCohort Studies; Female; Follow-Up Studies; Hepatectomy; Humans; Liver; Liver Function Tests; Liver Neoplasms; Male; Organ Size; Postoperative Complications; Probability; Retrospective Studies; Risk Assessment; Survival AnalysisFrozen section proceduremedicine.diagnostic_testbusiness.industryLiver NeoplasmsRetrospective cohort studyGeneral MedicineOrgan Sizemedicine.diseaseSurvival AnalysisSurgerySettore MED/18 - Chirurgia GeneraleLiverLiver biopsyFemaleLiver function testsbusinessViral hepatitisFollow-Up Studies
researchProduct

Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study

2016

Liver cancer represents a major clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from liver cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These tren…

MaleCancer ResearchDatabases FactualEpidemiologyTrends in survival0302 clinical medicineBelgiumCancer screeningMedicineCancer registries030212 general & internal medicineRegistriesYoung adultAged 80 and overmedicine.diagnostic_testMortality rateMedical recordLiver NeoplasmsMiddle Aged3. Good healthCancer registries; Europe; Excess mortality rate; Liver cancer; Net survival; Trends in survival;Survival RateEuropeOncologyItaly030220 oncology & carcinogenesisPopulation SurveillanceFemaleFranceLiver cancerLiver cancerSwitzerlandAdultAdolescentSocio-culturale03 medical and health sciencesYoung AdultNet survivalHumansAgedPortugalExcess mortality ratebusiness.industryPublic Health Environmental and Occupational Healthmedicine.diseaseCancer registrySpainLiver functionbusinessLiver function testsDemography
researchProduct

Endoscopic treatment of the "sump syndrome" after choledochoduodenostomy: a new technique using an amplatzer septal occluder.

2006

A 58-year-old male patient had been suffering for 35 years from recurrent cholangitis, biliary sludge and infection-induced stone formation after open cholecystectomy because of empyema of the gallbladder and severe acute and delayed postoperative complications. The pathophysiological origin of this chronic "sump syndrome" was a choledochoduodenostomy which had been performed prophylactically at the time of the initial operation. The patient agreed to an experimental treatment option with use of an Amplatzer atrial-septal defect (ASD) occluder for closure of the symptomatic choledochoduodenal fistula. The double-disc occluder was introduced through a 9 French diameter and 90 cm long sheath …

Malemedicine.medical_specialtyPostcholecystectomy syndromeFistulamedicine.medical_treatmentSump SyndromeProsthesis DesignProsthesis ImplantationLiver Function TestsmedicineHumansBiliary sludgeDuodenoscopyCholangiopancreatography Endoscopic RetrogradeCommon bile ductbusiness.industryGallbladderGastroenterologyMiddle Agedmedicine.diseaseEmpyemaSurgerymedicine.anatomical_structureTreatment OutcomeTherapeutic endoscopyCholedochostomyFluoroscopybusinessPostcholecystectomy SyndromeFollow-Up StudiesZeitschrift fur Gastroenterologie
researchProduct